Coach — Sulindac (The Kit)
Kit page: pharmacologic preconditioning residue after Fuel · Circadian · Strength — no cancer-prevention DIY.
The Kit · Sage · Surfer · Aspirin · Cancer
Sulindac is usually filed under "old NSAID, colon-polyp curiosity, GI risk." That filing is not wrong. In the working hypothesis behind this essay, it is incomplete. Laboratory work suggests that, at exposures well below its anti-inflammatory use, the same molecule can behave like a chemical version of ischemic preconditioning, the phenomenon in which a brief, survivable stress makes tissue harder to kill later. Normal cells and many cancer cells appear to read that signal in opposite ways. That makes sulindac scientifically interesting. It does not make it a supplement, and it does not make it a first move.
Safety first
The extended report opens with cautions: "This document is a working scientific hypothesis essay written for intellectual exploration. It is not medical advice, not a prescription, not a clinical protocol, and not a recommendation to start, stop, or change any medication — including sulindac (Clinoril) or any other NSAID." It continues: "Sulindac is a prescription nonsteroidal anti-inflammatory drug with established gastrointestinal, renal, and cardiovascular risks. The mitochondrial, preconditioning, retinal, anti-aging, and cancer-related mechanisms discussed here are drawn largely from preclinical work and from analogy to other stimuli (exercise, ischemic preconditioning, subthreshold laser). They have not been validated as approved indications. Low-dose or intermittent schedules described in the text are sketches for how a hypothesis might be tested, not doses to take." And: "Nothing in this essay should be used for self-treatment of aging, cancer, retinal disease, or metabolic performance. Decisions about prescription drugs, laser treatment, or any off-label use belong with a licensed clinician who knows the individual patient, the indication, and the contraindications."
The same boundaries apply to everyday decisions. Stomach, kidney, and heart risk, and any use alongside anticoagulants, belong with the prescribing physician. If a physician has already chosen sulindac or another anti-inflammatory for a reason, nothing here should rewrite that plan. Cancer-anxiety routines built around a prescription drug are a pattern to avoid. This essay makes no prevention claims and no eye-treatment claims.
The frame
In this series, aging is the progressive loss of the capacity to make ATP: fewer and poorer mitochondria, more damaged ones, less mitochondrial volume in tissue. Chronic disease is what that loss looks like when the body spends years in compensatory mode, with high insulin, inflammatory tone, poor overnight blood-pressure dipping, muscle loss, and scarring. Cancer is a further distortion of the same engine, the Warburg pattern of a cell that has traded flexible respiration for growth under stress.
Real food at the right times, a daily rhythm anchored to light, and strength and aerobic training are the three foundations because they change the number, quality, and use of mitochondria at once. Any drug is judged by a harsh standard: once those three are in place, what is left for it to do? Sulindac is interesting only if it occupies ground those three do not.
Two stories under one name
The first story is about repair chemistry. Methionine is the amino acid most easily damaged by oxidation, and the body repairs it with a family of enzymes called methionine sulfoxide reductases, which work catalytically rather than being used up. Sulindac is itself a sulfoxide, and the laboratory of Herbert Weissbach showed it is a direct substrate of those enzymes, which convert it into sulindac sulfide, the form that blocks COX and relieves inflammation. That explains why sulindac is a prodrug and why it sits inside a protein-repair network that declines with age. It does not explain the preconditioning findings.
The second story is independent of both the repair enzymes and COX. A related compound, sulindac sulfone, which neither feeds the repair enzymes nor blocks COX, still protects normal cells and still makes many cancer cells more vulnerable to oxidative stress. Other anti-inflammatories at matched concentrations, including aspirin and ibuprofen, do not reproduce that cancer-cell effect. Blocking a signaling enzyme called PKC abolishes the heart protection, and antioxidants blunt it. In operational terms, it is ischemic preconditioning without the ischemia.
The extended report insists on keeping the stories apart, because confusing them produces bad reasoning about timing. The repair story would want some continuous presence of the molecule. The preconditioning story wants a brief trigger, then a program, then quiet. Most of what follows is the second story.
Three clocks
The word preconditioning has been asked to do too much. A survivable stress today can make tissue harder to kill within an hour, within a day, and over a season, by different means. The first clock opens within minutes and fades within a few hours, carried by proteins and channels already present. The second opens after roughly half a day to a day, is carried by newly made protective proteins, and lasts two to three days. This is the clock the Weissbach laboratory mapped for sulindac: after 48 hours of low-dose feeding, rat hearts made more of these proteins and, when later subjected to an interruption of blood flow with no drug present, suffered smaller injuries. Blocking PKC abolished both the proteins and the protection. The same laboratory showed a similar pattern in the pigmented support layer of the retina. The second clock is real, and it is short.
The third clock is a family of slower traces: changes in how existing protective proteins work, marks on DNA and its packaging that alter later responses, inherited shapes of the mitochondrial network, trained memory in immune cells, and simply more cells surviving an injury that would otherwise have killed them. In the retina, the extended report points to a sub-threshold laser treatment whose effects are reported to last months, as evidence that one survivable stimulus can leave a lasting phenotype; this essay makes no claim about that treatment. The extended report is explicit that this does not transfer to an oral tablet by analogy. A laser deposits energy in tissue; a pill does not. None of the sulindac experiments tested whether protection lasted weeks or months after a short course.
Normal cells and cancer cells read the same signal differently
In normal cells, the trigger is a small, survivable pulse of reactive oxygen from mitochondria. Too little and nothing happens. Too much and it is injury, not a signal, which is why concentration and timing dominate the whole hypothesis. One form of PKC moves to the mitochondria, potassium channels in the mitochondrial membrane open, the cell's self-destruct pore becomes harder to trigger, and a later wave of protective genes follows. The organelle is not being stimulated. It is being told to refuse the death pore. The net result is that the next oxidative hit kills fewer cells.
Many cancer cells already sit near their limit for reactive oxygen, rely on fermentation even with oxygen present, and lean on a different, injury-prone form of PKC. In those cells, sulindac followed by an oxidant, or by a drug that forces sugar fuel into the mitochondria, produced a large burst of reactive oxygen, collapse of the mitochondrial membrane's charge, and cell death, while normal fibroblasts under the same conditions survived and were often protected. That is a metabolic selectivity argument, not conventional chemotherapy. It would fail in cancers with intact, flexible respiration, and it is a laboratory phenomenon, not evidence of lasting anti-cancer memory after a tablet. The essay on cancer sets out the wider metabolic frame.
Exercise already runs all three clocks
A single mild treadmill session puts a mouse heart into delayed protection the next day, through the same signaling chain, and blocking that chain blocks the protection. Exercise then does what no tablet does: it builds new mitochondria, clears damaged ones, remodels blood vessels, and releases signals from muscle to the rest of the body. Repeated training writes the third clock. A well-trained person is already living inside overlapping preconditioning windows most days of the week. In this hypothesis, strength and aerobic work are not lifestyle extras. They are the body's own multi-organ version of the pathway, and a chemical preconditioning agent is at best a partial mimic of one slice of it.
Why timing matters more than the molecule
Homeostasis returns a variable to its set point. Hormesis, discussed in its own essay, is a pulse that, after recovery, leaves the set point higher. Constant occupancy of a receptor usually produces the first; a spaced trigger with a decaying program produces the second. Animal and human work shows both outcomes. Packing many brief episodes of reduced blood flow into a few days, or giving certain drugs continuously, causes the protection to fade. Spacing the same stimuli preserves it, and training every other day does not use preconditioning up.
There is also a direct collision. COX-2 is one of the proteins that carries the second clock. In rabbits, low antiplatelet-range aspirin left late protection intact, while high anti-inflammatory-range aspirin abolished it. An anti-inflammatory proposed as a preconditioning trigger can light the fuse and dampen the effect at the same time. That is an independent argument, the extended report says, against continuous use for this purpose even if the second story is true, and a reason a drug given during another preconditioning window could interfere rather than help. Continuous anti-inflammatory use is a different idea from a pulse followed by recovery.
What is left, if anything
The residual case in the hypothesis is narrow: perhaps a chemical echo of late preconditioning on days the body is not generating that signal itself, perhaps a selective pressure against metabolically incompetent cells, and an older, COX-independent signal in the cancer literature that lifestyle does not fully explain. Each of those stays hypothesis, and none is a reason for anyone to take sulindac. Sulindac does not make new mitochondria, improve fuel, set the daily clock, or replace training. The neighboring essays on aging and methylene blue look at other drugs with mitochondrial reach through the same lens.
For the full argument, read the extended report on sulindac. The short version is in the lessons. Talk with your own physician before changing medications or supplements.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.